Multiple System Atrophy (MSA): The Most Severe Form of Dysautonomia

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disease that affects the autonomic nervous system, the cerebellum, and the basal ganglia simultaneously. It is one of the most severe forms of dysautonomia and is currently without a disease-modifying treatment. Understanding MSA — its subtypes, how it differs from other conditions, what to expect as it progresses, and how to manage symptoms — is essential for patients, caregivers, and the clinicians who support them.

What Is MSA?

MSA is caused by the abnormal accumulation of a protein called alpha-synuclein in glial cells (the support cells of the nervous system), particularly in oligodendrocytes. This accumulation — forming structures called glial cytoplasmic inclusions — leads to the progressive death of neurons in multiple brain regions, producing the characteristic combination of autonomic failure, parkinsonism, and cerebellar ataxia.

MSA affects approximately 4–5 people per 100,000, making it significantly rarer than Parkinson's disease. It typically presents in the sixth decade of life (average age of onset: 54–56 years), affects men and women roughly equally, and progresses more rapidly than Parkinson's disease, with a median survival of 6–10 years from symptom onset.

The Two Subtypes

MSA is classified into two subtypes based on the predominant motor features:

MSA-P (parkinsonian subtype): The dominant motor features are parkinsonism — bradykinesia (slowness of movement), rigidity, and postural instability. Tremor is less prominent than in Parkinson's disease. MSA-P is the more common subtype in Western countries, accounting for approximately 80% of cases.

MSA-C (cerebellar subtype): The dominant motor features are cerebellar ataxia — unsteady gait, incoordination, and speech difficulties (dysarthria). MSA-C is more common in Japan and other Asian countries.

Both subtypes share the same autonomic features, which are often the most disabling aspect of the disease.

Autonomic Features

The autonomic manifestations of MSA are severe and affect multiple organ systems:

Orthostatic hypotension is the most clinically significant autonomic feature. Blood pressure drops dramatically upon standing — often by 30–50 mmHg or more — causing severe lightheadedness, pre-syncope, and syncope. Unlike POTS, the heart rate does not rise appropriately in MSA because the autonomic damage impairs both the vasoconstrictive and heart rate responses. This neurogenic orthostatic hypotension is often the most disabling symptom and the primary driver of falls and injury.

Urinary dysfunction is nearly universal in MSA and often appears early in the disease course. Urinary urgency, frequency, incomplete emptying, and urinary retention are common. In men, erectile dysfunction is frequently an early symptom. Urinary symptoms in MSA are caused by damage to the autonomic nuclei that control bladder function.

Respiratory dysfunction is a distinctive feature of MSA that is not seen in other parkinsonian syndromes. Stridor (a high-pitched breathing sound caused by vocal cord paralysis) and sleep-disordered breathing (including central and obstructive sleep apnea) are common and can be life-threatening. Respiratory failure is a major cause of death in MSA.

Gastrointestinal dysfunction includes constipation, dysphagia (difficulty swallowing), and gastroparesis. Dysphagia in particular becomes a significant management challenge as the disease progresses.

Sudomotor dysfunction (abnormal sweating) is common, with both anhidrosis (reduced sweating) and hyperhidrosis (excessive sweating) reported.

How MSA Differs from Parkinson's Disease

MSA is frequently misdiagnosed as Parkinson's disease, particularly in the early stages. Several features help distinguish them:

The poor response to levodopa is one of the most important distinguishing features. Patients with MSA-P who are initially diagnosed with Parkinson's disease often have a partial or transient response to levodopa that diminishes over time, prompting reconsideration of the diagnosis.

Diagnosis

MSA is diagnosed clinically, based on the combination of autonomic failure and motor features (parkinsonism or cerebellar ataxia). Brain MRI can support the diagnosis by showing characteristic findings, including putaminal atrophy and the "hot cross bun" sign (a cross-shaped signal abnormality in the pons on T2-weighted imaging). However, these findings are not present in all patients, particularly early in the disease.

The diagnosis of MSA is currently confirmed only at autopsy by the finding of glial cytoplasmic inclusions containing alpha-synuclein. During life, the diagnosis is classified as "possible" or "probable" MSA based on clinical criteria.

Management

There is currently no treatment that slows or halts the progression of MSA. Management is entirely symptomatic and supportive.

Orthostatic hypotension is managed with the same approaches used in other forms of neurogenic OH: high salt and fluid intake, compression garments, head-of-bed elevation (to reduce supine hypertension), fludrocortisone, midodrine, and droxidopa (a norepinephrine precursor approved specifically for neurogenic OH). Supine hypertension — high blood pressure when lying flat — is a common complication of these treatments and requires careful monitoring.

Urinary dysfunction is managed with bladder training, scheduled voiding, anticholinergic medications (for urgency), alpha-blockers (for urinary retention in men), and intermittent catheterization when necessary.

Respiratory dysfunction requires sleep study evaluation and, in patients with stridor or significant sleep apnea, CPAP or BiPAP therapy. Tracheostomy may be required in advanced disease.

Motor symptoms are treated with physical therapy (to maintain mobility and reduce fall risk), speech therapy (for dysarthria and dysphagia), and occupational therapy (for adaptive strategies). Levodopa may provide modest benefit in MSA-P, particularly early in the disease.

Palliative care should be integrated early in the MSA disease course. Given the progressive nature and limited life expectancy, advance care planning — including discussions about feeding tubes, ventilatory support, and end-of-life preferences — is an essential part of comprehensive MSA care.

Support Resources

MSA is a rare disease, and patients and caregivers often feel isolated. The MSA Coalition (www.multiplesystematrophy.org) and the MSA Trust (UK) provide patient education, support groups, and research funding. Connecting with others who have experience with MSA — whether through patient organizations or online communities — can be invaluable for both patients and caregivers navigating this difficult disease.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.